Equillium, Inc. · NASDAQ:EQ
Equillium — Merger or Acquisition (September 2022)
9 slides from Equillium's merger presentation, Sep 7, 2022
Slide 1: Equillium Acquisition of Metacrine, Inc.
Equillium Acquisition of Metacrine, Inc. September 7, 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about Equillium, Inc. (the necessarily predict final results and that one or more of the clinical outcomes may “Company”). Statements contained in this presentation that are not historical facts are materially change as
Slide 3: Additional Information
Additional Information Additional Information and Where to Find it This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the proposed merger or otherwise. No offer of securities shall be
Slide 4: Equillium Acquisition of Metacrine, Inc.
Equillium Acquisition of Metacrine, Inc. Expected to add an estimated $33,000,000 in cash at closing Extends cash runway into 2024 • Stockholder vote required by both EQ & MTCR Preston Klassen, M.D., MHS, appointed to BOD at closing • All stock transaction • EQ share issuance based on MTCR net cash
Slide 5: Expanded and Diversified Pipeline
Expanded and Diversified Pipeline Drug Indication & Delivery Discovery & Pre-Clinical Phase 1 Phase 2 Phase 3 Status & Designations acute graft-versus-host • Pivotal study to support BLA filing disease Phase 3 initiated Q1 2022 • FDA Fast Track and Orphan EQ001 intravenous Drug Designations Itolizum
Slide 6: Corporate
a eQuilliumy — Corporate
Slide 7: Acquisition Takeaways
Acquisition Takeaways Expected to add $33 million in cash at closing and extend operating runway into 2024 • Adds to achievable catalysts with current runway • No additional FTEs and maintain sole discretion over the advancement of Metacrine programs • No increase to R&D opex All-Stock Transaction •
Slide 8: Catalysts & Milestones
Catalysts & Milestones Catalysts & Milestones Expected Timing EQUALISE Interim data from Phase 1b EQUALISE study - Type B patients (lupus nephritis) Mid 2022 Topline data from Phase 1b EQUALISE study - Type B patients (lupus nephritis) 2023 EQ101 Initiate Phase 2 study in alopecia areata 2H 2022 Int
Slide 9: Thank you
Thank you www.equilliumbio.com